antiviral activity; article; coronavirus disease 2019/dt [Drug Therapy]; disease severity; drug research; hospital admission; human; immune system; immunization; intensive care unit; monotherapy; nonhuman; particle size; Severe acute respiratory syndrome coronavirus 2; virus cell interaction; virus load; virus morphology; bamlanivimab/cb [Drug Combination]; bamlanivimab/cm [Drug Comparison]; bamlanivimab/dt [Drug Therapy]; etesevimab/cb [Drug Combination]; etesevimab/cm [Drug Comparison]; etesevimab/dt [Drug Therapy]; monoclonal antibody/dt [Drug Therapy]; placebo